LB PHARMACEUTICALS INC
LBRX evidence brief
What we can confirm
- BioSniper Score:
- 8.2 / 10
- Market Cap:
- $1.49B
What it means
What to watch
Prepared research question
What matters most for LBRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LBRX
LB PHARMACEUTICALS INC (LBRX) is a neuromedicines company advancing its lead candidate LB-102 through late-stage clinical trials for schizophrenia and bipolar depression, with a pipeline funded into 2029.
Key risk: Single-product dependency
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.49B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials for LB PHARMACEUTICALS INC.
LB PHARMACEUTICALS INC (LBRX) is a neuromedicines company advancing its lead candidate LB-102 through late-stage clinical trials for schizophrenia and bipolar depression, with a pipeline funded into 2029.
- Lead candidate LB-102 is in a pivotal Phase 3 NOVA-2 trial for schizophrenia and a Phase 2 ILLUMINATE-1 trial for bipolar depression [sec_mda · as of 2026-08-11].
- Cash, cash equivalents, and marketable securities were $327.8 million as of June 30, 2026, with an additional $150.0 million private placement in July 2026 [sec_mda · as of 2026-08-11].
- Net income was -$51.6M and shareholders' equity was $332.3M as of 2026-06-30 [sec].
- Accumulated deficit reached $200.2 million as of June 30, 2026, and the company expects continued operating losses [sec_mda · as of 2026-08-11].
- Topline results from the pivotal Phase 3 NOVA-2 trial are expected in the first half of 2027 [news · published 2026-07-22].
What works
- LB-102 is in late-stage development with a pivotal Phase 3 trial in schizophrenia and a Phase 2 trial in bipolar depression, targeting large, underserved markets [sec_mda · as of 2026-08-11].
- The company has a strong cash position of $327.8 million as of June 30, 2026, plus a $150 million private placement in July 2026, funding pipeline expansion into 2029 [sec_mda · as of 2026-08-11].
- Several branded antipsychotic drugs generate U.S. sales exceeding $1 billion annually, indicating significant commercial potential for approved novel therapies [sec_mda · as of 2026-08-11].
What to weigh
- The company has an accumulated deficit of $200.2 million as of June 30, 2026, and expects to continue generating operating losses and negative cash flows [sec_mda · as of 2026-08-11].
- LB Pharmaceuticals is heavily dependent on the success of its single lead product candidate, LB-102, which creates concentration risk [sec · filed 2026-06-10].
- Operating expenses are expected to increase substantially as the company advances clinical trials and scales for potential commercialization [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
LB-102 is in a pivotal Phase 3 trial for schizophrenia and a Phase 2 trial for bipolar depression.
“LB-102 is currently in late-stage clinical development for schizophrenia (pivotal Phase 3 NOVA-2 trial) and bipolar depression (Phase 2 ILLUMINATE-1 trial).”
SEC MD&A · August 11, 2026
Cash position as of June 30, 2026, was $327.8 million, with an additional $150 million private placement in July 2026.
“As of June 30, 2026, we had cash, cash equivalents and marketable securities of $327.8 million, which does not include net proceeds from our $150.0 million private placement in July 2026.”
SEC MD&A · August 11, 2026
Accumulated deficit was $200.2 million as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of $200.2 million.”
SEC MD&A · August 11, 2026
Topline results from the Phase 3 NOVA-2 trial are expected in the first half of 2027.
“now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027”
News · July 22, 2026
Risks & what to watch (3)›
Key risks
- Single-product dependency — Company depends on success of LB-102; failure could severely impact operations [sec · filed 2026-06-10].
- Continued operating losses — Accumulated deficit of $200.2M as of June 30, 2026; expects ongoing losses and negative cash flow [sec_mda · as of 2026-08-11].
- Rising expenses — Operating expenses expected to increase substantially with clinical and commercial scale-up [sec_mda · as of 2026-08-11].
What to watch
- Topline results from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia, expected in the first half of 2027 [news · published 2026-07-22].
- Pre-NDA meeting with FDA scheduled for the second half of 2027 [news · published 2026-07-22].
- Initiation of a Phase 2 trial of LB-102 for adjunctive treatment of major depressive disorder in early 2027 [news · published 2026-05-12].
- Pipeline expansion into new neuropsychiatric indications as announced [news · published 2026-08-11].
Sources: News · SEC filings · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run LB PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LB PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.09 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
77
Total value held
$693.3M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 3,352,804 | $82.7M |
| blackrock, inc. | 2,470,845 | $60.9M |
| ra capital management, l.p. | 2,208,604 | $54.5M |
| tcg crossover management, llc | 1,839,489 | $45.3M |
| commodore capital lp | 1,500,000 | $37.0M |
| caligan partners lp | 1,438,070 | $34.6M |
| spruce street capital lp | 1,376,159 | $33.6M |
| jpmorgan chase & co | 1,427,568 | $33.2M |
| trails edge capital partners, lp | 1,319,362 | $32.5M |
| nantahala capital management, llc | 1,052,894 | $26.0M |
Showing top 10 of 77 institutional holders of LB PHARMACEUTICALS INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 13.1%
- Days to cover
- 9.9
- Shares short
- 3,110,447
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LBRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for LB PHARMACEUTICALS INC?
LB PHARMACEUTICALS INC (LBRX) is a neuromedicines company advancing its lead candidate LB-102 through late-stage clinical trials for schizophrenia and bipolar depression, with a pipeline funded into 2029.
Who is the CEO of LB PHARMACEUTICALS INC?
Ms. Heather D. Turner Esq., J.D. is the chief executive officer of LB PHARMACEUTICALS INC (LBRX).
Where is LB PHARMACEUTICALS INC headquartered?
LB PHARMACEUTICALS INC (LBRX) is headquartered in New York, NY, United States.
What therapeutic areas does LB PHARMACEUTICALS INC focus on?
LB PHARMACEUTICALS INC develops therapies across Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.